Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

Introduction Optimal antithrombotic strategy following transcatheter aortic valve replacement (TAVR) is still unknown. We hypothesised that the direct factor Xa inhibitor edoxaban can potentially prevent subclinical leaflet thrombosis and cerebral embolisation compared with conventional dual antipla...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyung Won Kim, Dae-Hee Kim, Hanbit Park, Do-Yoon Kang, Jung-Min Ahn, Anthony Y T Wong, Simon C C Lam, Wei-Hsian Yin, Jeng Wei, Yung-Tsai Lee, Hsien-Li Kao, Mao-Shin Lin, Tsung-Yu Ko, Won-Jang Kim, Se Hun Kang, Euihong Ko, Hyun Jung Koo, Dong Hyun Yang, Joon-Won Kang, Seung Chai Jung, Jae-Hong Lee, Sung-Cheol Yun, Seung-Jung Park, Duk-Woo Park
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/1/e042587.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/11/1/e042587.full

Similar Items